Gyre Therapeutics (GYRE) Non-Current Receivables (2023 - 2024)
Gyre Therapeutics (GYRE) reported Non-Current Receivables of $5.0 million for Q4 2024, up 5.89% year-over-year from $4.7 million in Q1 2024, and up 2.04% on a QoQ basis from $4.9 million in Q3 2024.
Gyre Therapeutics (GYRE) has 2 years of Non-Current Receivables data on file, last reported at $5.0 million in Q4 2024.
- Quarterly Non-Current Receivables rose 5.89% year-over-year to $5.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5.0 million (up 5.89% YoY) and the FY2024 annual result came in at $5.0 million, up 5.89% from the prior year.
- Non-Current Receivables advanced to $5.0 million in Q4 2024 per GYRE's latest filing, from $4.9 million in the prior quarter.
- Across five years, Non-Current Receivables topped out at $5.0 million in Q4 2024 and bottomed at $4.6 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Mar 31, 2024 | 4.78 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 4.61 Mn |
| Mar 31, 2023 | 4.55 Mn |